At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Post-Mkt 08-07 19:23:53 EDT
1.61
+0.03
+1.90%
盘后1.61
+0.000.00%
18:15 EDT
High1.64Low1.58Vol21.71K
Open1.64D1 Closing1.58Amplitude3.80%
Mkt Cap6.77MTradable Cap5.75MTotal Shares4.20M
T/O34.53KT/O Rate0.61%Tradable Shares3.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview
Reuters  ·  01:38
Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview
Imunon Schedules Q2 Results, Business Update Conference Call
Reuters  ·  08-04
Imunon Schedules Q2 Results, Business Update Conference Call
Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview
Reuters  ·  07-31
Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview
Imunon Says Phase 3 Ovation 3 Ovarian Cancer Trial Enrollment Outpaces Plan
Reuters  ·  07-30
Imunon Says Phase 3 Ovation 3 Ovarian Cancer Trial Enrollment Outpaces Plan
Imunon - Imnn-001 Demonstrates Favorable Safety Profile with no Serious Immune-Related Adverse Events
THOMSON REUTERS  ·  07-30
Imunon - Imnn-001 Demonstrates Favorable Safety Profile with no Serious Immune-Related Adverse Events
Imunon - Reports Enrollment Rate Exceeding Forecast in Ovation 3 Trial
THOMSON REUTERS  ·  07-30
Imunon - Reports Enrollment Rate Exceeding Forecast in Ovation 3 Trial
Imunon Reports Strong Enrollment Momentum in Phase 3 Ovation 3 Trial of Imnn-001 in Advanced Ovarian Cancer
THOMSON REUTERS  ·  07-30
Imunon Reports Strong Enrollment Momentum in Phase 3 Ovation 3 Trial of Imnn-001 in Advanced Ovarian Cancer
Imunon - Projects Enrollment Completion in Q2 2029 for Ovation 3 Trial
THOMSON REUTERS  ·  07-30
Imunon - Projects Enrollment Completion in Q2 2029 for Ovation 3 Trial
Imunon Announces Press Release Available
Reuters  ·  07-23
Imunon Announces Press Release Available
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
GlobeNewswire  ·  07-23
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Imunon General Counsel Susan Eylward Disposes of 2,150 Common Shares Worth $3,830.44
Reuters  ·  07-22
Imunon General Counsel Susan Eylward Disposes of 2,150 Common Shares Worth $3,830.44
Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response
MT Newswires Live  ·  07-21
Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response
Imunon announces new preliminary data from IMNN-001 trial
TIPRANKS  ·  07-21
Imunon announces new preliminary data from IMNN-001 trial
Imunon - Imnn-001 Under Evaluation in Phase 3 Ovation 3 Trial for Advanced Ovarian Cancer
THOMSON REUTERS  ·  07-21
Imunon - Imnn-001 Under Evaluation in Phase 3 Ovation 3 Trial for Advanced Ovarian Cancer
Imunon Reports Positive Phase 2 Mrd Clinical Data for Imnn-001, Demonstrating the Successful Overcoming of Historical Il-12 Safety Barriers in Frontline Ovarian Cancer
THOMSON REUTERS  ·  07-21
Imunon Reports Positive Phase 2 Mrd Clinical Data for Imnn-001, Demonstrating the Successful Overcoming of Historical Il-12 Safety Barriers in Frontline Ovarian Cancer
Imunon - no Cytokine Release Syndrome or Serious Immune-related Adverse Events Observed with Imnn-001
THOMSON REUTERS  ·  07-21
Imunon - no Cytokine Release Syndrome or Serious Immune-related Adverse Events Observed with Imnn-001
Imunon - Imnn-001 Demonstrates Lower Mrd Rate, Higher Ctdna Clearance, and Higher Ned Rate vs Control
THOMSON REUTERS  ·  07-21
Imunon - Imnn-001 Demonstrates Lower Mrd Rate, Higher Ctdna Clearance, and Higher Ned Rate vs Control
Imunon - Imnn-001 Shows Highly Favorable Safety and Tolerability Profile
THOMSON REUTERS  ·  07-21
Imunon - Imnn-001 Shows Highly Favorable Safety and Tolerability Profile
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
GlobeNewswire  ·  07-21
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Imunon Files Form 3 for CFO Joshua Blacher
Reuters  ·  07-08
Imunon Files Form 3 for CFO Joshua Blacher
No data available

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--